MAUI, Hawaii, March 27, 2007 /PRNewswire-FirstCall/ -- Bioponic Phytoceuticals, Inc. ("Bioponic" or "the Company") today announced that its Curecumin(TM) (a Bioresonant Phytotherapeutic(R) form of Turmeric containing curcumin in a liquid nasal delivery system) may be an important treatment for Lung Cancer.
In a recent study published in Science Direct, "Induction of Apoptosis in Human Lung Cancer Cells by Curcumin," conducted at the Department of Medicine, Pediatrics and Family and Preventive Medicine, School of Medicine, University of California, San Diego, scientists concluded, "Curcumin, a phenolic compound from the rhizome of the plant Curcuma longa has anti-inflammatory, antioxidant and anti-cancer activities... This study investigated the cellular and molecular changes induced by curcumin leading to the induction of apoptosis in human lung cancer cell lines -- A549 and H1299... Curcumin inhibited the growth of both the cell lines in a concentration dependent manner... Curcumin induced apoptosis in both the lung cancer cell lines."
Lung cancer is the leading cause of cancer death in the United States, causing 30% of all cancer deaths. It is estimated by the American Cancer Society that "More than 213,380 in the United States will be diagnosed with lung cancer this year and there will be 160,390 deaths from lung cancer in 2007."
"We are particularly interested in the potential of our Curecumin(TM) product to provide a viable treatment strategy for those with lung cancer. Especially, because the liquid form of Curecumin, in a nasal delivery system, will send the formula directly to the lungs. If proven effective, we may have an efficacious, cost effective, natural treatment for lung cancer sufferers." said Steven M. Schorr, Chairman & CEO -- Bioponic Phytoceuticals, Inc.
Bioponic Phytoceuticals is engaged in the development,
production and distribution of Bioresonant Phytother